

# Exhibit 472

Report 72: “Other AESIs” Included MERS, Multiple Organ Dysfunction Syndrome (MODS), Herpes Infections, and 96 DEATHS. 15 Patients Were Under Age 12, Including Six Infants.

<https://dailyclout.io/report-72-other-aesis-included-mers-multiple-organ-dysfunction-syndrome-mods-herpes-infections-and-96-deaths-15-patients-were-under-age-12-including-six-infants/>

(<https://dailyclout.io/>)



(<https://dailyclout.io/cart/>)

(<https://www.facebook.com/dailyclout/>)

(<https://twitter.com/DailyClout?lang=en>)

(<https://www.youtube.com/channel/UCU-FMBZNtCdSiYBgJdvJmXw>)

(<https://www.instagram.com/dailyclout.io/>)

**ALL POSTS**

**BULLETIN BOARD**

**DAILYCLOUT LAWSUIT**

**OPINION**



**PFIZER REPORTS**

Search



DailyClout



Pfizer Reports

## Report 72: "Other AESIs" Included MERS, Multiple Organ Dysfunction Syndrome (MODS), Herpes Infections, and 96 DEATHS. 15 Patients Were Under Age 12, Including Six Infants.

May 30, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a report about Other Adverse Events of Special Interest (AESIs) found in Pfizer document

*5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021* ([https://www.phmpt.org/wp-content/uploads/2022/04/reissue\\_5.3.6-postmarketing-experience.pdf](https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf))

(a.k.a., "5.3.6"). This category of AESIs is not related to a specific set of medical conditions or a specific organ. Rather, it contains medical conditions such as herpes virus infections,

MERS (Middle East Respiratory Syndrome)

(<https://www.hopkinsmedicine.org/health/conditions-and-diseases/middle-east-respiratory-syndrome-mers>)

MODS (Multiple Organ Dysfunction Syndrome)

(<https://www.verywellhealth.com/multiple-organ-dysfunction-syndrome-5223630>)

; symptoms such as fever and inflammation; and non-medical-related issues like manufacturing issues.

It is important to note that the AESIs in the 5.3.6 document were reported to Pfizer for **only a 90-day period** starting on December 1, 2020, the date of the United Kingdom's public rollout of Pfizer's COVID-19 experimental mRNA "vaccine" product.

Key points of this report include:

- **Death was listed as the "relevant [adverse] event outcome" for 96 individuals** in this category.
- **Fifteen patients were under 12 years of age, including six infants;** and Pfizer's mRNA "vaccine" was not approved for use in people under age 16 at the time of 5.3.6's data collection.
- Of those reports with gender known, **76% were female and 24% were male, a greater than 3:1 female to male ratio.**
- There were **391 herpes infections** reported, including shingles, [herpetic eye infections \(https://www.healthline.com/health/eye-herpes\)](https://www.healthline.com/health/eye-herpes), and non-shingles herpes infections.
- There were **18 Multiple Organ Dysfunction (MODS) adverse events.**
- Onset of adverse events, a.k.a. latency, was from within 24 hours to 61 days with **half occurring within one day.**
- This category included 8,152 patients/cases, which is 19.4% of the total cases reported to Pfizer during its 90-day post-marketing safety surveillance.
- Non-elderly adults had almost six times the number of adverse events seen in elderly adults.
- Fever was the most common adverse event.
- Pfizer concluded: "This cumulative case review does not raise new safety issues. Surveillance will continue." To date, no follow-up, updated, and comprehensive safety report has been publicly released.

Please read this important two-page report below.



War Room/DailyClout Pfizer Document Analysis

SOURCE

[https://www.phmpf.org/wp-content/uploads/2022/04/reissue\\_5.3.6-postmarketing-experience.pdf](https://www.phmpf.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf)

5.3.6 AE REPORTING PERIOD:

"Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021."

ABBREVIATIONS:

5.3.6 : Pfizer source document

SOC : System Organ Class

AE : Adverse Event

AESI : Adverse Event of Special Interest

EUA : Emergency Use Authorization by FDA

PM : Post-Marketing

BNT162b2 : Pfizer's mRNA COVID-19 vaccine

SEQUELAE: an abnormal condition resulting from a previous disease, injury, or other trauma

AGE GROUPS defined in 5.3.6 (p. 25 footnote) :

Adult	18 - 64
Elderly	≥ 65
Child	2 - 11
Adolescent	12 - < 18
Infant	1 – 23 months

AUTHORS:

Dr Joseph Gehrett MD  
 Dr Barbara Gehrett MD  
 Dr Chris Flowers MD  
 Loree Britt



22May23

Post-Marketing Team Micro-Report 13:  
 Other Adverse Events of Special Interest Review of 5.3.6



Death was the "relevant event outcome" for 96 individuals, which is 7.8% of 1,223 deaths from all causes reported in this 90-day report.

<p><b>Other AESIs</b></p> <p><i>Search criteria: Herpes viral infections (HLI) (Primary Path) OR PTs adverse event following immunisation; Inflammation; Manufacturing laboratory analytical testing issue; Manufacturing materials issue; Manufacturing production issue; MERS-CoV test; MERS-CoV test negative; MERS-CoV test positive; Middle East respiratory syndrome; Multiple organ dysfunction syndrome; Occupational exposure to communicable disease; Patient</i></p>	<ul style="list-style-type: none"> <li>Number of cases: 8152 (19.4% of the total PM dataset), of which 4977 were medically confirmed and 3175 non-medically confirmed;</li> <li>Country of incidence (&gt; 20 occurrences): UK (2715), US (2421), Italy (710), Mexico (223), Portugal (210), Germany (207), France (186), Spain (183), Sweden (133), Denmark (127), Poland (120), Greece (95), Israel (79), Czech Republic (79), Romania (57), Hungary (53), Finland (52), Norway (51), Latvia (49), Austria (47), Croatia (42), Belgium (41), Canada (39), Iceland (34), Serbia (28), Iceland (25), Netherlands (22). The remaining 127 cases were from 21 different countries;</li> <li>Subjects' gender (n=7829): female (5969), male (1860);</li> <li>Subjects' age group (n=7479): Adult (6330), Elderly (1125), Adolescent, Child (9 each), Infant (6);</li> </ul>
<p><b>AESIs' Category</b></p> <p><i>Isolation; Product availability issue; Product distribution issue; Product supply issue; Pyrexia; Quarantine; SARS-CoV-1 test; SARS-CoV-1 test negative; SARS-CoV-1 test positive</i></p>	<p><b>Post-Marketing Cases Evaluation*</b></p> <p><b>Total Number of Cases (N=42086)</b></p> <ul style="list-style-type: none"> <li>Number of relevant events: 8241, of which 3674 serious, 4568 non-serious;</li> <li>Most frequently reported relevant PTs (&gt;6 occurrences) included: Pyrexia (7666), Herpes zoster (2599), Inflammation (132), Oral herpes (80), Multiple organ dysfunction syndrome (18), Herpes virus infection (17), Herpes simplex (13), Ophthalmic herpes zoster (10), Herpes ophthalmic and Herpes zoster reactivation (6 each);</li> <li>Relevant event onset latency (n=6836): Range from &lt;24 hours to 61 days, median 1 day;</li> <li>Relevant events outcome: fatal (96), resolved/resolving (5008), resolved with sequelae (84), not resolved (1429) and unknown (1685).</li> </ul> <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>

[https://www.phmpf.org/wp-content/uploads/2022/04/reissue\\_5.3.6-postmarketing-experience.pdf](https://www.phmpf.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf)

- Adverse Events were reported to Pfizer during a 90-day period, following the December 1, 2020, public rollout of its COVID-19 experimental "vaccine" product.

- In the Pfizer 5.3.6 document, these AEs were categorized by System Organ Classes (SOC) – in other words, by systems in the body.

- Of those with known age, 1,125 were elderly; 6,330 were non-elderly adult; nine were adolescents; nine were children; and six were infants.

- Of those whose gender was known (7,829), 5,969 (76%) were female and 1,860 (24%) were male with a ratio of 3.2:1 female to male.

IMPORTANT NOTE:

This category of AESIs is not related to a particular set of medical conditions or a specific organ of the body. The search criteria range from medical conditions (Herpes virus infections, Middle East Respiratory Syndrome, Multiple Organ Dysfunction Syndrome) to symptoms (fever, inflammation) to non-medical-related issues (manufacturing laboratory analytical testing issues, manufacturing production issues). The Pfizer report only specifically identified those conditions that had six or more occurrences.

This SOC included 8,152 patients, 19.4% of the total cases/patients in the 90-day period of this report. The cases were reported from 48 countries. In this total group of patients, there were 8,241 adverse events of which 3,674 (45%) were serious and 4,568 (55%) were non-serious.

Fever was the most common event (7,666). Herpes virus infection, including shingles, herpetic eye infections, and non-shingles herpes infections, comprised 391 events. Inflammation was listed with 132 events, but these were not defined further as to type or bodily location. Multiple organ dysfunction syndrome had 18 events.

Death was the "relevant event outcome" for 96 individuals, which is 7.8% of 1,223 deaths from all cases reported in this 90-day report and for 1% of the patients in this SOC. Of the 8,241 total events, outcomes of "resolved/resolving" were listed for 5,008 events (61%), "resolved with sequelae" for 84 (1%), "not resolved" for 1,429 (17%), and "unknown" for 1,685 (20%). The time from injection to adverse event onset was from within 24 hours to 61 days with half occurring within one day.

This report was written exclusively for DailyClout by the members of the War Room/DailyClout Pfizer Documents Analysis Project team. It may not be copied or republished without written permission from DailyClout or a full credit and link to [DailyClout.io](https://dailyclout.io).

<https://dailyclout.io/wp-content/uploads/p1-Post-Marketing-Team-Other-AESIs-MicroReport.pdf> (<https://dailyclout.io/wp-content/uploads/p1-Post-Marketing-Team-Other-AESIs-MicroReport.pdf>)



**SOURCE:**  
[https://www.phmpt.org/wp-content/uploads/2022/04/reissue\\_5.3.6-postmarketing-experience.pdf](https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf)

To summarize this SOC, the search terms used seem to consist mainly of nonlethal conditions, yet **there were 96 deaths**. Herpes virus infections can cause a great deal of pain, which can be chronic and debilitating, and herpes eye infections have the potential to cause impaired vision or blindness. Yet, death other than from herpes encephalitis would be rare. However, encephalitis and encephalopathy are reported by Pfizer in different SOCs.

Certainly, multiple organ dysfunction syndrome can cause death in a significant number of cases, but only 18 were reported. **If all 18 led to death, from where did the other 78 deaths come?**

Inflammation types are not defined, but Pfizer has a separate SOC for Immune-Mediated/Autoimmune that would capture most of the purely inflammatory diseases. **So, we are left with no clarity or explanation for at least 78 deaths.**

Extremely high fevers can be lethal, and febrile seizures were reported by Pfizer in a separate SOC. **Of the 8,241 events, 8,207 were presented because each occurred six or more times.** What were the missing 34 events, and why were they not enumerated?

Finally, we are faced with the **15 individuals under 12 years of age (six of whom were infants), and nine adolescents** (with an unknown number of these less than age 16). **Pfizer's drug was not approved for those under age 16 at the time of 5.3.6 data collection, and the dosage given to these children and young people had not been determined.** We do not know how many deaths occurred in this underage group.

It is surprising that, in this SOC, **non-elderly adults had almost six times the number of adverse events seen in elderly adults.** In the first 90 days of rollout, priority for the vaccine was given to the elderly, high-risk patients, and health care workers. This distribution of adverse events is unexplained.



**Despite the incomplete and inconsistent reporting  
and 96 deaths,  
Pfizer's conclusion remains the same:**

**"This cumulative case review does not raise new safety issues.  
Surveillance will continue."**

**Note:** As of the date of this team report, no follow-up, updated, and comprehensive safety report (comparable to 5.3.6) has been publicly released.

---

**Post-Marketing Team's CONCLUSION**  
**RECALL this unsafe "vaccine."**

---

This report was written exclusively for DailyClout by the members of the War Room/DailyClout Pfizer Documents Analysis Project team. It may not be copied or republished without written permission from DailyClout or a full credit and link to [DailyClout.io](https://dailyclout.io).



<https://dailyclout.io/wp-content/uploads/p2-Post-Marketing-Other-AESIs-MicroReport.pdf> (<https://dailyclout.io/wp-content/uploads/p2-Post-Marketing-Other-AESIs-MicroReport.pdf>)

**Order Your Copy of the Pfizer Reports Paperback Book.**

(<https://dailyclout.io/product/war-room-dailyclout-pfizer-documents-analysis-volunteers-reports-book-paperback/>)

**Please support DailyClout.** (<https://dailyclout.io/donate/>)

**Become a DailyClout Member.** (<https://dailyclout.io/memberships/>)

---

**Spread the love**

(<https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fdailyclout.io%2Freport-72-other-aesis-included-mers-multiple-organ-dysfunction-syndrome-mods-herpes-infections-and-96-deaths-15-patients-were-under-age-12-including-six-infants%2F>)

([http://twitter.com/intent/tweet?](http://twitter.com/intent/tweet?text=Report%2072%3A%20%22Other%20AESI)

[text=Report%2072%3A%20%22Other%20AESI](http://twitter.com/intent/tweet?text=Report%2072%3A%20%22Other%20AESI)  
72-other-aesis-included-mers-multiple-organ-

([https://gettr.com/share?](https://gettr.com/share?text=Report%2072%3A%20%22Other%20AESI)

[text=Report%2072%3A%20%22Other%20AESI](https://gettr.com/share?text=Report%2072%3A%20%22Other%20AESI)  
72-other-aesis-included-mers-multiple-organ-

(<https://dailyclout.io/report-72->

[other-aesis-included-mers-multiple-organ-dysfunction-syndrome-mods-herpes-infections-and-96-deaths-15-patients-were-under-age-12-including-six-infants/](https://dailyclout.io/report-72-))